This study aims to demonstrate a clinically significant improvement in Forced Expiratory
Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled
by Inhaled Corticosteroid (ICS) therapy. Patients will be treated with QAW039, an active
comparator, or placebo. This will be a randomized, placebo-controlled, dose-ranging,
multi-centre trial.